ArticleBMC musculoskeletal disorders2022
Spanish translation, cultural adaptation and validation of the SarQoL®: a specific health-related quality of life questionnaire for sarcopenia.
Article in BMC musculoskeletal disorders, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it, 23 citations in OpenAlex.
- Psychometric Properties of the SarQoL Questionnaire: A Systematic Review and Meta-Analysis.Journal of cachexia, sarcopenia and muscle · 2025Pooled it
- Sarcopenia and health-related quality of life: A systematic review and meta-analysis.Journal of cachexia, sarcopenia and muscle · 2023Pooled it
- Validity and reliability of the Spanish version of the Dental Impact on Daily Living (Sp-DIDL) questionnaire in a Spanish population: a cross-sectional study.BMC oral health · 2026Article
- The influence of sarcopenia on health-related quality of life among older patients with gastrointestinal cancer: an assessment using the SarQoLAging clinical and experimental research · 2025Article
- Validating Patient-Reported Outcomes and Surveys in Other Languages.Current reviews in musculoskeletal medicine · 2025Review
- Addressing Digital Disparities in Alzheimer Disease by Improving Access to Alzheimer Resources for Spanish-Speaking Latino or Latina Individuals in Los Angeles County: Mixed Methods Study.Journal of medical Internet research · 2025Article
- Cross-cultural adaptation and validation of the Sinhala version of SarQoLBMC geriatrics · 2025Article
- A Prospective Controlled Study on the Longitudinal Effects of Rehabilitation in Older Women with Primary Sarcopenia.Life (Basel, Switzerland) · 2025Article
- Article
- Validation of the German version of the SarQoLAging clinical and experimental research · 2024Article
- Content validity of SarQoL, a quality of life questionnaire specific to sarcopenia.Aging clinical and experimental research · 2024Article
- Assessing quality of life with SarQol is useful in screening for sarcopenia and sarcopenic obesity in older women.Aging clinical and experimental research · 2023Article
- Measuring health-related quality of life in sarcopenia: summary of the SarQoL psychometric properties.Aging clinical and experimental research · 2023Review
- Evaluation of the sarcopenia quality of life (SarQoL) questionnaire in community dwelling outpatient postmenopausal hungarian women.BMC musculoskeletal disorders · 2023Article
- SarQoL Questionnaire in Community-Dwelling Older Adults under EWGSOP2 Sarcopenia Diagnosis Algorithm: A New Screening Method?International journal of environmental research and public health · 2022Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn 2015, a specific health-related quality of life questionnaire for sarcopenia, SarQoL®, was developed and validated in French. Since then, SarQoL® has been adapted and validated in different languages. We prepared a translation, cultural adaptation and validation of the psychometric properties of the SarQoL® into Spanish.
methodsA cross-sectional study with 86 participants. The translation and adaptation followed international guidelines with two direct translations, a synthesized version of the direct translations, two reverse translations, consensus by an expert committee of a pre-final version, pre-test by end users and final version. The discriminative power (logistic regression analyses), construct validity (Pearson and Spearman´s correlation), internal consistency (Cronbach´s alpha coefficient), test-retest reliability (intraclass correlation coefficient) and ceiling and floor effects were analyzed.
resultsThe Spanish version showed good construct validity (high correlation with comparable domains of the SF-36), high internal consistency (Cronbach's alpha coefficient: 0.84) and excellent test-retest reliability (ICC: 0.967, 95%, CI 0.917 - 0.989). However, it had no discriminative power between sarcopenic and non-sarcopenic participants defined with the EWGSOP and FNIH diagnostic criteria of sarcopenia. It did show discriminative power between patients with decreased vs normal muscle strength (54.9 vs. 62.6, p 0.009) and low vs. normal physical performance (57.3 vs. 70.2; p 0.005). No ceiling or floor effect was found.
conclusionsThe Spanish version of SarQoL® has similar psychometric properties to those of the original version of the instrument. It did not discriminate between sarcopenic and non-sarcopenic patients diagnosed according to the EWGSOP or FNIH criteria, but it did with those with low muscle strength and low physical performance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.